GSK’s high-level management makeover continues as CEO Emma Walmsley oversees changing of the guard

June 12, 2018 09:42 AM EDT

John Carroll

GSK’s high-level management makeover continues as CEO Emma Walmsley oversees changing of the guard

The big shakeup in the inner executive circle around CEO Emma Walmsley is continuing today, with two top appointments at GlaxoSmithKline — and one key exit.

Regis Simard

Luc Debruyne is out at the end of this year as president of vaccines after a 5-year stint. Roger Connor, who runs global manufacturing and supply, takes that role September 1. Regis Simard is being appointed president, pharmaceutical supply chain, and will join the corporate executive team.

Walmsley has been doing a total overhaul of the top team in the wake of her arrival in the CEO suite. The changeover includes a new R&D chief — Hal Barron — and plenty of new faces from the oncology world as GSK looks to break out of the innovation doldrums.

Image: Roger Connor and Luc Debruyne. GSK

Author

John Carroll

EDITOR & FOUNDER

john@endpointsnews.com @JohnCendpts

John Carroll on LinkedIn

John Hood [file photo]

August 16, 2019 10:12 AM EDTUpdated 03:34 PM

John Carroll

Pharma

Regulatory

UPDATE: Celgene and the scientist who championed fedratinib's rise from Sanofi's R&D graveyard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

August 14, 2019 10:42 AM EDTUpdated August 15, 11:41 AM

John Carroll

People

UPDATED: AveXis scientific founder was axed — and Novartis names a new CSO in wake of an ethics scandal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ENDPOINTS CAREERS

Structural Biologist/Biomolecular NMR Investigator

Skyhawk Therapeutics

Waltham, MA

view job offer post your job now

August 16, 2019 02:53 PM EDTUpdated 03:36 PM

John Carroll

R&D

AbbVie gets its FDA OK for JAK inhibitor upadacitinib, but don’t look for this one to hit execs’ lofty expectations

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

August 16, 2019 09:38 AM EDTUpdated 10:22 AM

John Carroll

Pharma

The top 10 franchise drugs in biopharma history will earn a total of $1.4T (trillion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

August 15, 2019 11:33 AM EDTUpdated August 16, 04:41 AM

John Carroll

People

Pharma

UPDATED: Scientist-CEO accused of improperly using confidential info from unicorn Alector

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ENDPOINTS CAREERS

Bioinformatics Software Developer

Skyhawk Therapeutics

Waltham, MA, USA

view job offer post your job now

August 15, 2019 08:16 AM EDTUpdated 08:55 AM

Endpoints Contributor

Biotech Voices

China

China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

August 14, 2019 08:56 AM EDTUpdated 09:54 AM

John Carroll

Deals

As disaster struck, AbbVie’s Rick Gonzalez swooped in on Allergan with an offer Brent Saunders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

Brent Saunders

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

August 14, 2019 06:56 AM EDTUpdated 11:54 AM

John Carroll

Pharma

R&D

AstraZeneca's juggernaut PARP player Lynparza scoops up another dominant win in PhIII as the FDA adds a 'breakthrough' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ENDPOINTS CAREERS

Recruiting Manager/Sr.Manager/Associate Director

Skyhawk Therapeutics

Waltham, MA, USA

view job offer post your job now

August 16, 2019 09:59 AM EDT

Amber Tong

Pharma

ICER blasts FDA, PTC and Sarepta for high prices on DMD drugs Emflaza, Exondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.